FREMONT, Calif., Feb. 25, 2016 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused
on gastrointestinal and cardio-renal diseases, today announced that
it will report its financial results for the fourth quarter and
full year ended December 31, 2015, on
Friday, March 4, 2016. Following the
announcement, the Ardelyx management team will host a live
conference call and webcast at 8:00am
ET to review the Company's financial results and provide a
business update.
![Ardelyx logo Ardelyx logo](http://photos.prnewswire.com/prnvar/20140619/119451)
The live webcast can be accessed by visiting the investor
section of Ardelyx's website at ir.ardelyx.com. Please connect to
the Company's website at least 15 minutes prior to the live webcast
to ensure adequate time for any software download that may be
needed to access the webcast. Alternatively, please call
1-855-296-9612 (US) or 920-663-6277 (International) to listen to
the conference call. The conference ID number for the live call
will be 58231765. Following the webcast, an archived version of the
call will be available until March 18,
2016.
About Ardelyx
Ardelyx is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of innovative,
minimally-systemic, small molecule therapeutics that work
exclusively in the gastrointestinal tract to treat gastrointestinal
and cardio-renal diseases. Ardelyx has developed a proprietary drug
discovery and design platform enabling it, in a rapid and
cost-efficient manner, to discover and design novel drug
candidates. Utilizing this platform, Ardelyx has discovered and
designed tenapanor, which it is evaluating for the treatment of
constipation-predominant irritable bowel syndrome, or IBS-C, and
management of hyperphosphatemia in patients with end stage renal
disease. In addition to tenapanor, Ardelyx is developing RDX022, a
non-absorbed polymer for the treatment of hyperkalemia, or high
potassium, in kidney and heart disease patients. Ardelyx is also
advancing several research programs focused in gastrointestinal and
cardio-renal diseases. Ardelyx is located in Fremont, California. For more information,
please visit Ardelyx's website at www.ardelyx.com.
Logo - http://photos.prnewswire.com/prnh/20140619/119451
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ardelyx-to-report-fourth-quarter-and-full-year-2015-financial-results-on-march-4th-2016-300225948.html
SOURCE Ardelyx